Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study.
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
01
03
2021
received:
23
12
2020
accepted:
04
03
2021
pubmed:
14
3
2021
medline:
25
6
2021
entrez:
13
3
2021
Statut:
ppublish
Résumé
Data regarding outcome of COVID-19 in patients with autoimmune hepatitis (AIH) are lacking. We performed a retrospective study on patients with AIH and COVID-19 from 34 centers in Europe and the Americas. We analyzed factors associated with severe COVID-19 outcomes, defined as the need for mechanical ventilation, intensive care admission, and/or death. The outcomes of patients with AIH were compared to a propensity score-matched cohort of patients without AIH but with chronic liver diseases (CLD) and COVID-19. The frequency and clinical significance of new-onset liver injury (alanine aminotransferase > 2 × the upper limit of normal) during COVID-19 was also evaluated. We included 110 patients with AIH (80% female) with a median age of 49 (range, 18-85) years at COVID-19 diagnosis. New-onset liver injury was observed in 37.1% (33/89) of the patients. Use of antivirals was associated with liver injury (P = 0.041; OR, 3.36; 95% CI, 1.05-10.78), while continued immunosuppression during COVID-19 was associated with a lower rate of liver injury (P = 0.009; OR, 0.26; 95% CI, 0.09-0.71). The rates of severe COVID-19 (15.5% versus 20.2%, P = 0.231) and all-cause mortality (10% versus 11.5%, P = 0.852) were not different between AIH and non-AIH CLD. Cirrhosis was an independent predictor of severe COVID-19 in patients with AIH (P < 0.001; OR, 17.46; 95% CI, 4.22-72.13). Continuation of immunosuppression or presence of liver injury during COVID-19 was not associated with severe COVID-19. This international, multicenter study reveals that patients with AIH were not at risk for worse outcomes with COVID-19 than other causes of CLD. Cirrhosis was the strongest predictor for severe COVID-19 in patients with AIH. Maintenance of immunosuppression during COVID-19 was not associated with increased risk for severe COVID-19 but did lower the risk for new-onset liver injury during COVID-19.
Sections du résumé
BACKGROUND AND AIMS
Data regarding outcome of COVID-19 in patients with autoimmune hepatitis (AIH) are lacking.
APPROACH AND RESULTS
We performed a retrospective study on patients with AIH and COVID-19 from 34 centers in Europe and the Americas. We analyzed factors associated with severe COVID-19 outcomes, defined as the need for mechanical ventilation, intensive care admission, and/or death. The outcomes of patients with AIH were compared to a propensity score-matched cohort of patients without AIH but with chronic liver diseases (CLD) and COVID-19. The frequency and clinical significance of new-onset liver injury (alanine aminotransferase > 2 × the upper limit of normal) during COVID-19 was also evaluated. We included 110 patients with AIH (80% female) with a median age of 49 (range, 18-85) years at COVID-19 diagnosis. New-onset liver injury was observed in 37.1% (33/89) of the patients. Use of antivirals was associated with liver injury (P = 0.041; OR, 3.36; 95% CI, 1.05-10.78), while continued immunosuppression during COVID-19 was associated with a lower rate of liver injury (P = 0.009; OR, 0.26; 95% CI, 0.09-0.71). The rates of severe COVID-19 (15.5% versus 20.2%, P = 0.231) and all-cause mortality (10% versus 11.5%, P = 0.852) were not different between AIH and non-AIH CLD. Cirrhosis was an independent predictor of severe COVID-19 in patients with AIH (P < 0.001; OR, 17.46; 95% CI, 4.22-72.13). Continuation of immunosuppression or presence of liver injury during COVID-19 was not associated with severe COVID-19.
CONCLUSIONS
This international, multicenter study reveals that patients with AIH were not at risk for worse outcomes with COVID-19 than other causes of CLD. Cirrhosis was the strongest predictor for severe COVID-19 in patients with AIH. Maintenance of immunosuppression during COVID-19 was not associated with increased risk for severe COVID-19 but did lower the risk for new-onset liver injury during COVID-19.
Identifiants
pubmed: 33713486
doi: 10.1002/hep.31797
pmc: PMC8250536
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2099-2109Subventions
Organisme : NIAAA NIH HHS
ID : R01 AA024762
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : ErratumIn
Informations de copyright
© 2021 by the American Association for the Study of Liver Diseases.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Hepatology. 2020 Dec 17;:
pubmed: 33332624
Hepatology. 2020 Aug;72(2):671-722
pubmed: 31863477
Clin Gastroenterol Hepatol. 2021 Jul;19(7):1469-1479.e19
pubmed: 32950749
Liver Int. 2021 Jan;41(1):237-238
pubmed: 33159405
Hepatol Commun. 2020 Jun 09;:
pubmed: 32838102
Hepatology. 2018 Apr;67(4):1560-1599
pubmed: 29405329
Hepatology. 2020 Aug;72(2):753-769
pubmed: 32500593
N Engl J Med. 2020 Apr 2;382(14):1293-1295
pubmed: 32101660
J Hepatol. 2021 Jan;74(1):148-155
pubmed: 32750442
J Hepatol. 2020 Nov;73(5):1063-1071
pubmed: 32526252
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Autoimmun. 2020 Nov;114:102506
pubmed: 32563547
Gut. 2021 Mar;70(3):531-536
pubmed: 32660964
J Hepatol. 2015 Oct;63(4):971-1004
pubmed: 26341719
Hepatology. 2020 Sep;72(3):807-817
pubmed: 32473607
Gastroenterology. 2020 Aug;159(2):481-491.e3
pubmed: 32425234
Hepatology. 2007 Dec;46(6):2032-9
pubmed: 18046720
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Hepatology. 2021 Feb;73(2):811-820
pubmed: 33150599
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Hepatology. 2020 Dec;72(6):1900-1911
pubmed: 32964510
Ann Rheum Dis. 2020 Jul;79(7):859-866
pubmed: 32471903